<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932215</url>
  </required_header>
  <id_info>
    <org_study_id>7242</org_study_id>
    <nct_id>NCT02932215</nct_id>
  </id_info>
  <brief_title>Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder</brief_title>
  <official_title>Pilot Study: Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 10 week, open-label, prospective study, involving 10 volunteer participants with
      cannabis use disorder to test the feasibility and safety of using lorcaserin in addition to
      the feasibility, likability, and utility of a mobile sensor device in cannabis users. The
      study will be entirely outpatient. Upon study entry, participants will begin clinic visits at
      the Substance Treatment and Research Service (STARS) clinic. All consented participants will
      receive a Fitbit Charge HR device in week 1 to wear for the entire study and receive
      lorcaserin beginning in week 2 for a total of 8 weeks (weeks 2-9). At the beginning of week
      10 following discontinuation of lorcaserin, the participants will continue to wear the Fitbit
      Charge HR device for this final week following completion of the medication trial. All
      participants will visit the clinic twice weekly to provide urine toxicology on THC, report on
      adverse events, complete additional assessments (outlined below), and upload de-identified
      data from the Fitbit Charge HR device to the secure encrypted Fitabase database. Study
      assessments will be collected at baseline, throughout the study, and 1 week following
      medication discontinuation. All participants will also receive medical management, a
      medication adherence focused psychosocial intervention that facilitates compliance with study
      medication and other study procedures, including adherence to wearing the Fitbit Charge HR
      device, and promotes abstinence from cannabis and other substances. Progressive voucher
      incentives will be provided for compliance with visit attendance and study procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design Overview: This is a 10 week, open-label, prospective study, involving 10 volunteer
      participants with cannabis use disorder to test the feasibility and safety of using
      lorcaserin in addition to the feasibility, likability, and utility of a mobile sensor device
      in cannabis users. The study will be entirely outpatient Upon study entry, participants will
      begin clinic visits at the Substance Treatment and Research Service (STARS) clinic. All
      consented participants will receive a Fitbit charge HR mobile device in week 1 to wear for
      the entire study and receive lorcaserin beginning in week 2 for a total of 8 weeks (weeks
      2-9). At the beginning of week 10 following discontinuation of lorcaserin, the participants
      will continue to wear the device for this final week following completion of the medication
      trial. All participants will visit the clinic twice weekly to provide urine toxicology on
      THC, report on adverse events, complete additional assessments (outlined below), and upload
      de-identified data from the device to a secure encrypted database. Study assessments will be
      collected at baseline, throughout the study, and 1 week following medication discontinuation.
      All participants will also receive medical management, a medication adherence focused
      psychosocial intervention that facilitates compliance with study medication and other study
      procedures, including adherence to wearing the device, and promotes abstinence from cannabis
      and other substances. Progressive voucher incentives will be provided for compliance with
      visit attendance and study procedures.

      The specific aims of the project are:

        1. To determine whether lorcaserin is associated with a reduction from baseline in cannabis
           use in individuals with cannabis use disorder seeking treatment.

        2. To determine the tolerability of lorcaserin in this population.

        3. To evaluate the feasibility and likability of incorporating a mobile health sensor
           device in a treatment study for cannabis use disorder.

      The primary outcome measures are:

        1. Lorcaserin will significantly reduce cannabis use during the study period as measured by
           self-report (Timeline Followback) and creatinine-normalized quantitative THC urine
           levels.

        2. Lorcaserin will be well tolerated in participants with cannabis use disorder as measured
           by the proportion of participants completing the study, adherence to medication, and the
           proportion of participants experiencing adverse events.

        3. Participants will find it feasible and likeable to utilize the Fitbit Charge HRTM in the
           study as measured by selfreport assessment of liking and adherence to wearing the device

      Secondary aims include:

        1. To evaluate the effect of medication treatment for cannabis use disorder on activity,
           sleep, stress, and quality of life as measured with a mobile sensor device and
           self-report assessments in individuals with cannabis use disorder.

        2. To evaluate the correlation between summarized Fitbit Charge HR health sensor measures
           and self-report assessments of sleep, stress, and quality of life in addition to
           participants' use of cannabis and cannabis withdrawal at baseline, during, and after a
           treatment trial.

      The secondary outcome measures include:

        1. Medication treatment will increase positive health behaviors including activity and
           improve sleep (increase total sleep time and percentage deep sleep) in addition to
           decreasing stress and improving quality of life as measured by summarized daily total
           steps, sleep duration and quality, and summarized stress score measured with device in
           conjunction with improvement in the Pittsburgh Sleep Quality Inventory (PSQI), decreased
           Perceived Stress Scale score (PSS), and improvement on Quality of Life, Enjoyment, and
           Satisfaction Questionnaire (QLESQ), as compared to baseline. Negative health behaviors
           (poor sleep, decreased activity, increased stress) will be highest within subjects
           before starting treatment and with initial abstinence from cannabis when withdrawal
           symptoms are most prominent. Positive health behaviors will increase during treatment
           within subject, and particularly towards the second half of treatment as reduction in
           cannabis use or abstinence is sustained.

        2. The device measures and self-report measures will directly correlate, as expected; ie:
           increased sleep and increased % of deep sleep will correlate with higher PSQI scores.
           When participants are using baseline levels of cannabis or are in cannabis withdrawal,
           they will have device measures consistent with negative health behaviors (poor sleep,
           decreased activity, increased stress). When they reduce cannabis use or achieve
           abstinence for a sustained period (any 14 days), an association with positive health
           behaviors as measured by the mobile device (adequate sleep, adequate activity, decreased
           stress) will increase.

      The objective of the pilot is to obtain preliminary data on cannabis use patterns,
      tolerability of this medication, and sleep, quality of life and activity patterns in
      individuals with cannabis use disorder before conducting a larger trial with lorcaserin and
      to inform future applications of mobile sensors to cannabis use disorder treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cannabis use</measure>
    <time_frame>weeks 1-10</time_frame>
    <description>urine toxicology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to device</measure>
    <time_frame>weeks 1-10</time_frame>
    <description>days device is worn</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of implementing mobile health device in treatment trial for CUD</measure>
    <time_frame>assessed once at 10weeks (end of study)</time_frame>
    <description>5 question self-report on likability of device; eg: Question 1: did you like wearing the mobile sensor device to track your progress during treatment? Yes or No; Question 2: Would you continue to wear the mobile sensor device to track your behaviors? Yes or No; etc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cannabis Use</measure>
    <time_frame>weeks 1-10</time_frame>
    <description>Timeline Followback</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adherence to medication</measure>
    <time_frame>weeks 1- 8</time_frame>
    <description>number of pills taken</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive open label lorcaserin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorcaserin</intervention_name>
    <description>Open label</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>Belviq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fitbit Charge HR</intervention_name>
    <description>This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data</description>
    <arm_group_label>All participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals between the ages of 18-60

          -  Meets DSM-V criteria for a current cannabis use disorder

          -  Seeking treatment for cannabis use disorder

          -  THC-positive urine drug screen

          -  Capable of giving informed consent and complying with study procedures

          -  Has access to a mobile device with IOS7 or Android 4.4.2 capabilities or more recent
             operating systems

          -  Not underweight (Defined as BMI â‰¥18.5)

        Exclusion Criteria:

          -  Lifetime history of DSM-V diagnosis of schizophrenia, schizoaffective disorder, or
             bipolar disorder

          -  Current DSM-V criteria for any other psychiatric disorder supported by the MINI that
             in the investigator's judgment is unstable, would be disrupted by the study
             medication, or is likely to require new pharmacotherapy or psychotherapy during the
             study period. Individuals who are currently stable on a psychotropic medication for at
             least 3 months may be included if in the investigator's opinion the psychotropic
             medication the patient is taking is compatible with the study medication (lorcaserin).

          -  Individuals who meet DSM-V criteria for any substance use disorder other an cannabis,
             caffeine or nicotine use disorders

          -  Pregnancy, lactation, or failure to use adequate contraceptive method in female
             patients who are currently engaging in sexual activity with men

          -  Unstable medical conditions, such as AIDS, cancer, uncontrolled hypertension (blood
             pressure &gt; 140/90), uncontrolled diabetes, pulmonary hypertension or heart disease

          -  Legally mandated to participate in a substance use disorder treatment program

          -  Current or recent history of significant violent orsuicidal behavior, risk for suicide
             or homicide psychiatrist

          -  Currently meets DSM-V diagnosis for an eating disorder or is underweight (defined as
             BMI &lt;18.5)

          -  Elevated liver function tests (AST and ALT &gt; 3 times the upper limit of normal) or
             impaired renal function

          -  Known history of allergy, intolerance, or hypersensitivity to lorcaserin

          -  Concurrent use of migraine medications ergotamine (Cafergot, Ergomar) or
             dihydroergotamine (Migranal), 5HT2B receptor agonists like cabergoline, or medications
             metabolized by CYP2D6 (thioridazine, tamoxifen, metoprolol, aripiprazole, codeine,
             etc)

          -  No access to mobile device with IOS7 or Android 4.4.2 capabilities or more recent
             operating systems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chrsitina A Brezing, MD</last_name>
    <phone>646-774-6132</phone>
    <email>brezing@nyspi.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia Substance Treatment and Research Service</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina A Brezing, MD</last_name>
      <phone>646-774-6132</phone>
      <email>brezing@nyspi.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Frances R Levin, MD</last_name>
      <phone>6467746137</phone>
      <email>frl2@columbia.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mobile health device</keyword>
  <keyword>substance abuse treatment</keyword>
  <keyword>quality of life</keyword>
  <keyword>lorcaserin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

